Intraocular inflammation incidence and real-world safety of intravitreal faricimab treatment across retinal indications
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-025-04931-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Wan-Ju Annabelle Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Chi Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Inflammation, Retinal Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
This multi-institutional real-world study evaluated the incidence of intraocular inflammation (IOI) following faricimab treatment across major retinal diseases. The study reviewed records of adults treated with faricimab between January 2022 and April 2025 and classified them into four disease cohorts: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and polypoidal choroidal vasculopathy (PCV). Patients with a recent history of IOI were excluded. In total, 7784 patients were analyzed, including 4085 with nAMD, 1456 with DME, 1057 with RVO, and 1166 with PCV. Mean ages varied by disease group, ranging from 65.5 years in DME to 75.6 years in nAMD, and more than half of all patients had prior intravitreal anti-VEGF therapy. Within 180 days of treatment initiation, the incidence of new-onset IOI was 0.54% with nAMD, 1.24% with DME, 1.23% with RVO, and 1.03% with PCV. Overall, IOI risk ranged from approximately 0.5 to 1.2%, with higher rates observed among patients with DME and RVO. These findings highlight the importance of ongoing pharmacovigilance as newer retinal therapeutics enter clinical practice, and they provide timely evidence to support safety monitoring in real-world ophthalmology settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Chi Mei Medical Center, Tainan, Taiwan.
- School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Population Health Data Center, National Cheng Kung University, Tainan, Taiwan.
- Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
- School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. edward_lai@mail.ncku.edu.tw.
- Population Health Data Center, National Cheng Kung University, Tainan, Taiwan. edward_lai@mail.ncku.edu.tw.
ORCID-Profile: Wan-Ju Annabelle Lee, Daniel Hsiang-Te Tsai, Shih-Chieh Shao, Edward Chia-Cheng Lai
Zitieren
APA
Lee, W. A., Tsai, D. H., Shao, S. C., & Lai, E. C. (2026). Intraocular inflammation incidence and real-world safety of intravitreal faricimab treatment across retinal indications. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04931-0
Vancouver
Lee WA, Tsai DH, Shao SC, Lai EC. Intraocular inflammation incidence and real-world safety of intravitreal faricimab treatment across retinal indications. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04931-0
BibTeX
@article{Lee2026,
author = {Lee, Wan-Ju Annabelle and Tsai, Daniel Hsiang-Te and Shao, Shih-Chieh and Lai, Edward Chia-Cheng},
title = {Intraocular inflammation incidence and real-world safety of intravitreal faricimab treatment across retinal indications},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-025-04931-0}
}
EUVIMED